EpiBone

United States
Jersey City, New Jersey, United States, 07302

Company profile

EpiBone company profile

EpiBone is a pioneering regenerative medicine company at the forefront of bone and cartilage repair. Leveraging the power of stem cells, biomimicry, and 3D fabrication, they are developing a pipeline of innovative products with enormous potential to revolutionize orthopedic repair. Their lead product, a living, anatomically precise 3D bone graft, completed its Phase I/IIa clinical trial in August 2023. The rest of their pipeline focuses on cartilage repair, and includes an allogeneic osteochondral plug, whose IND was approved in July 2023. Their cartilage portfolio also includes an injectable cartilage filler that was partly funded by the Department of Defense.

Business identity

Contact email
[email protected]
Phone number
2016300133
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2013-01-01, Year

Headquarters

Postal code
07302
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
15
Total equity funding
$12.3M
Last funding
Series Unknown / $4.3M / 2025-10-24
Last equity funding
Series Unknown / $4.3M
Investors
9
Lead investors
3
Founders
3
Articles
33

Founders and investors

Founders

Elisa CimettaNina TandonSarindr Bhumiratana

Lead investors

Kendall Capital PartnersNetScientific PLCTachyon Ventures

Investors

Covenant Venture CapitalEMV CapitalLifespan Vision VenturesPlum AlleyTachyon Ventures